Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis
Authors:
- Stefano BoniniSBStefano Bonini
- Alessandro LambiaseALAlessandro Lambiase
- Paolo RamaPRPaolo Rama
- Wendy ChaoWCWendy Chao
- Elisabeth MessmerEMElisabeth Messmer
- Pasquale AragonaPAPasquale Aragona
- Gerd GeerlingGGGerd Geerling
- Leonardo MastropasquaLMLeonardo Mastropasqua
- Rita MencucciRMRita Mencucci
Open Access
- 1 September 2018
- journal article
- editorial
- Published by Elsevier in Ophthalmology
- Vol. 125 (9) , 1468-1471
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic KeratitisOphthalmology, 2018
- Understanding the Pathogenesis of Neurotrophic Keratitis: The Role of Corneal NervesJournal of Cellular Physiology, 2016
- Safety and Pharmacokinetics of Escalating Doses of Human Recombinant Nerve Growth Factor Eye Drops in a Double-Masked, Randomized Clinical TrialBioDrugs, 2013
- Topical Treatment with Nerve Growth Factor for Corneal Neurotrophic UlcersNew England Journal of Medicine, 1998